Literature DB >> 11529684

Muscarinic receptors in the mammalian heart.

S Dhein1, C J van Koppen, O E Brodde.   

Abstract

In the mammalian heart, cardiac function is under the control of the sympathetic and parasympathetic nervous system. All regions of the mammalian heart are innervated by parasympathetic (vagal) nerves, although the supraventricular tissues are more densely innervated than the ventricles. Vagal activation causes stimulation of cardiac muscarinic acetylcholine receptors (M-ChR) that modulate pacemaker activity via I(f) and I(K.ACh), atrioventricular conduction, and directly (in atrium) or indirectly (in ventricles) force of contraction. However, the functional response elicited by M-ChR-activation depends on species, age, anatomic structure investigated, and M-ChR-agonist concentration used. Among the five M-ChR-subtypes M(2)-ChR is the predominant isoform present in the mammalian heart, while in the coronary circulation M(3)-ChR have been identified. In addition, evidence for a possible existence of an additional, not M(2)-ChR in the heart has been presented. M-ChR are subject to regulation by G-protein-coupled-receptor kinase. Alterations of cardiac M(2)-ChR in age and various kinds of disease are discussed. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11529684     DOI: 10.1006/phrs.2001.0835

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  76 in total

Review 1.  Muscarinic receptors: what we know.

Authors:  Harriette M Scarpero; Roger R Dmochowski
Journal:  Curr Urol Rep       Date:  2003-12       Impact factor: 3.092

Review 2.  Muscarinic regulation of cardiac ion channels.

Authors:  Robert D Harvey; Andriy E Belevych
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

Review 3.  Functional M3 muscarinic acetylcholine receptors in mammalian hearts.

Authors:  Zhiguo Wang; Hong Shi; Huizhen Wang
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

4.  Functional M3 cholinoreceptors are present in pacemaker and working myocardium of murine heart.

Authors:  Denis V Abramochkin; Svetlana V Tapilina; Galina S Sukhova; Eugen E Nikolsky; Leniz F Nurullin
Journal:  Pflugers Arch       Date:  2012-02-15       Impact factor: 3.657

Review 5.  Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson; Jerry J Buccafusco; Christopher Chapple; William Chet de Groat; Alison D Fryer; Gary Kay; Alan Laties; Neil M Nathanson; Pankaj Jay Pasricha; Alan J Wein
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

6.  Cyclic AMP-dependent inotropic effects are differentially regulated by muscarinic G(i)-dependent constitutive inhibition of adenylyl cyclase in failing rat ventricle.

Authors:  R I Hussain; F Afzal; H K Mørk; J M Aronsen; I Sjaastad; J-B Osnes; T Skomedal; F O Levy; K A Krobert
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

7.  Segment-dependent expression of muscarinic acetylcholine receptors and G-protein coupling in the equine respiratory tract.

Authors:  G Abraham; C Kottke; H Ammer; S Dhein; F R Ungemach
Journal:  Vet Res Commun       Date:  2006-12-15       Impact factor: 2.459

8.  Influence of age on inducibility and cholinergic modulation of arrhythmia in isolated rat right atria.

Authors:  D M Faria; A G Viviane; K M Galvão; A Caricati-Neto; C M G Godoy
Journal:  Age (Dordr)       Date:  2008-11-19

Review 9.  Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil.

Authors:  Hanming Zhang; Xuejun Wang
Journal:  Future Cardiol       Date:  2015-03

10.  Genetic disruption of G proteins, G(i2)alpha or G(o)alpha, does not abolish inotropic and chronotropic effects of stimulating muscarinic cholinoceptors in atrium.

Authors:  P Boknik; S Grote-Wessels; G Barteska; M Jiang; F U Müller; W Schmitz; J Neumann; L Birnbaumer
Journal:  Br J Pharmacol       Date:  2009-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.